Setoperone

Setoperone
Clinical data
Other names	R-52245; R52245
Drug class	Serotonin 5-HT2A receptor antagonist
ATC code	None;
Identifiers
	IUPAC name 6-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}-7-methyl-2,3-dihydro-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;
CAS Number	86487-64-1 ;
PubChem CID	68604;
ChemSpider	61870 ;
UNII	BQ67CS3Q3E;
KEGG	D02686 ;
CompTox Dashboard (EPA)	DTXSID9057848 ;
Chemical and physical data
Formula	C21H24FN3O2S
Molar mass	401.50 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(=O)N2CCSC2=N1)CCN3CCC(CC3)C(=O)C4=CC=C(C=C4)F;
	InChI InChI=1S/C21H24FN3O2S/c1-14-18(20(27)25-12-13-28-21(25)23-14)8-11-24-9-6-16(7-10-24)19(26)15-2-4-17(22)5-3-15/h2-5,16H,6-13H2,1H3 ; Key:RBGAHDDQSRBDOG-UHFFFAOYSA-N ;
	(what is this?) (verify)

Setoperone (INNTooltip International Nonproprietary Name; USANTooltip United States Adopted Name; developmental code name R-52245) is a compound that is a ligand to the 5-HT_2A receptor.^[1] It can be radiolabeled with the radioisotope fluorine-18 and used as a radioligand with positron emission tomography (PET). Several research studies have used the radiolabeled setoperone in neuroimaging for the studying neuropsychiatric disorders, such as depression^[2] or schizophrenia.^[3] The drug was first described by at least 1984.^[1]